Skip to main content

Table 1 Baseline characteristics

From: Racial/ethnic differences in 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer

 

Non-Hispanic White (n = 115,651)

Hispanic White (n = 8213)

Black (n = 10,814)

Asian/Pacific Islander (n = 5455)

 
 

N

%

N

%

N

%

N

%

P

Age

        

 < 0.001

  < 50 years

20,838

18.0

2095

25.5

2309

21.4

1838

33.7

 

 50 years or older

94,813

82.0

6118

74.5

8505

78.6

3617

66.3

 

Facility

        

 < 0.001

 Nonacademic

78,847

68.2

5108

62.2

5978

55.3

2939

53.9

 

 Academic

34,139

29.5

2777

33.8

4412

40.8

2225

40.8

 

 Not available

2665

2.3

328

4.0

424

3.9

291

5.3

 

Insurance

        

 < 0.001

 None

916

0.8

349

4.2

236

2.2

98

1.8

 

 Private

69,729

60.3

4624

56.3

5617

51.9

3678

67.4

 

 Government

43,908

38.0

3129

38.1

4837

44.7

1615

29.6

 

 Not available

1098

0.9

111

1.4

124

1.1

64

1.2

 

Income

        

 < 0.001

 Above median

69,938

60.5

4525

55.1

3767

34.8

3968

72.7

 

 Below median

28,332

24.5

2720

33.1

5459

50.5

769

14.1

 

 Not available

17,381

15.0

968

11.8

1588

14.7

718

13.2

 

Education

        

 < 0.001

 Above median

66,644

57.6

3481

42.4

3076

28.4

3099

56.8

 

 Below median

31,800

27.5

3777

46.0

6154

56.9

1640

30.1

 

 Not available

17,207

14.9

955

11.6

1584

14.6

716

13.1

 

CDS

        

 < 0.001

 0

98,533

85.2

6955

84.7

8276

76.5

4655

85.3

 

 1

13,807

11.9

1014

12.3

1953

18.1

667

12.2

 

 2 + 

3311

2.9

244

3.0

585

5.4

133

2.4

 

Year

        

 < 0.001

 2006–2013

46,201

39.9

3508

42.7

4062

37.6

1935

35.5

 

 2014–2017

68,843

59.5

4611

56.1

6692

61.9

3493

64.0

 

Histology

        

 < 0.001

 Ductal or lobular carcinoma

99,610

86.1

7075

86.1

9145

84.6

4645

85.2

 

 Other

16,041

13.9

1138

13.9

1669

15.4

810

14.8

 

PR

        

 < 0.001

 Positive

105,011

90.8

7481

91.1

9472

87.6

5002

91.7

 

 Negative

10,640

9.2

732

8.9

1342

12.4

453

8.3

 

T staging

        

 < 0.001

 1

86,854

75.1

6018

73.3

7659

70.8

3889

71.3

 

 2

27,139

23.5

2096

25.5

2979

27.5

1510

27.7

 

 3

1658

1.4

99

1.2

176

1.6

56

1.0

 

N staging

        

 < 0.001

 0

98,537

85.2

6965

84.8

9040

83.6

4681

85.8

 

 1a

17,114

14.8

1248

15.2

1774

16.4

774

14.2

 

Grade

        

 < 0.001

 1

33,175

28.7

2157

26.3

2434

22.5

1320

24.2

 

 2

61,582

53.2

4376

53.3

5659

52.3

3071

56.3

 

 3

16,665

14.4

1402

17.1

2341

21.6

899

16.5

 

 Other

71

0.1

5

0.1

5

0.0

2

0.0

 

 Not available

4158

3.6

273

3.3

375

3.5

163

3.0

 

RS

        

 < 0.001

 0–15

573,239

495.7

4073

49.6

4797

44.4

2685

49.2

 

 16–25

42,037

36.3

2943

35.8

3833

35.4

1942

35.6

 

  ≥ 26

16,285

14.1

1197

14.6

2184

20.2

828

15.2

 

LVSI

        

 < 0.001

 No

89,180

77.1

6064

73.8

8228

76.1

4149

76.1

 

 Yes

13,892

12.0

1075

13.1

1293

12.0

753

13.8

 

 Not available

12,579

10.9

1074

13.1

1293

12.0

553

10.1

 

Chemotherapy

       

 < 0.001

 No

92,083

79.6

6348

77.3

8078

74.7

4181

76.6

 

 Yes

23,568

20.4

1865

22.7

2736

25.3

1274

23.4

 

Radiation

        

 < 0.001

 No

35,409

30.6

2775

33.8

3272

30.3

1883

34.5

 

 Yes

79,007

68.3

5317

64.7

7393

68.4

3519

64.5

 

 Not available

1209

1.0

119

1.4

143

1.3

51

0.9

 

Surgery

        

 < 0.001

 Lumpectomy

78,791

68.1

5374

65.4

7411

68.5

3402

62.4

 

 Mastectomy

36,831

31.8

2839

34.6

3400

31.4

2052

37.6

 

 Other

29

0.0

0

0.0

3

0.0

1

0.0

 

Margin

        

0.01

 Negative

111,871

96.7

7915

96.4

10,409

96.3

5251

96.3

 

 Positive

3384

2.9

270

3.3

354

3.3

178

3.3

 

 Not available

396

0.3

28

0.3

51

0.5

26

0.5

 
  1. N Number, CDS Charlson-Deyo Comoribidty Score, PR Progesterone receptor, RS 21-gene recurrence score, LVSI Lymphovascular invasion